Investigating how to turn off cancer-related enzymes to discover new drugs
Base-Editing the Cancer Kinome to Enable Drug Discovery
This study is looking at how certain enzymes called kinases affect cancer cells, especially in breast cancer, by using new techniques to turn them off, which could help find better treatments for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10687392 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of kinase enzymes in cancer cell function by using advanced base editing techniques to selectively turn off these enzymes. By manipulating the activity of kinases, which are crucial for cell signaling and growth, the research aims to identify new therapeutic targets for cancer treatment. The approach allows for precise modifications across the entire kinome, potentially leading to the discovery of effective drug combinations for various cancers, particularly breast cancer. Patients may benefit from the insights gained into how these enzymes contribute to cancer progression and treatment resistance.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with breast cancer or other malignancies that may benefit from targeted kinase therapies.
Not a fit: Patients with non-malignant conditions or those whose cancers are not driven by kinase dysregulation may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new targeted therapies for breast cancer and other malignancies.
How similar studies have performed: Previous research has shown promise in targeting kinases for cancer treatment, indicating that this approach could lead to significant advancements in oncology.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Vasan, Neil — Columbia University Health Sciences
- Study coordinator: Vasan, Neil
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.